We then determined the half-maximal inhibitory concentration of the specific and potent FLT3 inhibitor, gilteritinib, in human FLT3-ITD leukemia cell lines after 24 h of treatment (Fig. 4a). The gene discussed is FLT3; the disease is leukemia.